Sign In
Buy JAGX
$2.92
-0.300 (-9.32%)
At Close: Jun 03, 2026
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
03:11pm, Friday, 10'th Apr 2026
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
08:30am, Wednesday, 08'th Apr 2026
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyr
Jaguar Health Reports 2025 Financials
08:30am, Tuesday, 07'th Apr 2026
Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® a
Head to Head Review: Jaguar Animal Health (NASDAQ:JAGX) and Telomir Pharmaceuticals (NASDAQ:TELO)
01:42am, Monday, 06'th Apr 2026
Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) and Jaguar Animal Health (NASDAQ: JAGX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
09:00am, Thursday, 02'nd Apr 2026
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID)
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
09:00am, Wednesday, 18'th Mar 2026
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction coul
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("
Financial Contrast: Universe Pharmaceuticals (NASDAQ:UPC) versus Jaguar Animal Health (NASDAQ:JAGX)
01:42am, Sunday, 15'th Mar 2026
Jaguar Animal Health (NASDAQ: JAGX - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
09:00am, Wednesday, 11'th Mar 2026
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday,
Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure in
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
09:00am, Tuesday, 03'rd Mar 2026
As announced , Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
09:00am, Monday, 02'nd Mar 2026
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc
Jaguar Health Announces a Special One-time Stock Dividend
09:00am, Wednesday, 18'th Feb 2026
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc. (N
Jaguar Animal Health (NASDAQ:JAGX) Stock Crosses Below Fifty Day Moving Average – What’s Next?
01:42am, Tuesday, 17'th Feb 2026
Jaguar Animal Health, Inc. (NASDAQ: JAGX - Get Free Report) passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $0.93 and traded as low as $0.59.
